<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01169259</url>
  </required_header>
  <id_info>
    <org_study_id>2009P-001217</org_study_id>
    <secondary_id>U01CA138962</secondary_id>
    <secondary_id>R01CA138962</secondary_id>
    <nct_id>NCT01169259</nct_id>
  </id_info>
  <brief_title>Vitamin D and Omega-3 Trial (VITAL)</brief_title>
  <acronym>VITAL</acronym>
  <official_title>Vitamin D and Omega-3 Trial (VITAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmavite LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pronova BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BASF</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VITamin D and OmegA-3 TriaL (VITAL) is a randomized clinical trial in 25,871 U.S. men and
      women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or
      omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart
      disease, and stroke in people who do not have a prior history of these illnesses. The 5-year
      intervention phase (study pill-taking, median 5.3 years) has ended; post-intervention
      observational follow-up of study participants is ongoing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The VITamin D and OmegA-3 TriaL (VITAL) is a randomized clinical trial of vitamin D (in the
      form of vitamin D3 [cholecalciferol]) and marine omega-3 fatty acid (eicosapentaenoic acid
      [EPA] + docosahexaenoic acid [DHA]) supplements in the primary prevention of cancer and
      cardiovascular disease (CVD). Existing data from laboratory studies, epidemiologic research,
      small primary prevention trials, and/or large secondary prevention trials strongly suggest
      that these nutritional agents may reduce risk for cancer or CVD, but large primary prevention
      trials with adequate dosing in general populations are lacking.

      VITAL tested the independent effects of vitamin D and omega-3 fatty acid supplementation on
      risk for developing cancer and CVD (primary, secondary, and other outcomes are specified in
      the Outcome Measures section). VITAL also explored (a) whether vitamin D and omega-3 fatty
      acid supplements exhibit synergistic or additive effects on cancer and CVD risk and (b)
      whether the effect of each supplement on cancer and CVD risk varies by baseline blood levels
      or intake of vitamin D and EPA+DHA, race/ethnicity, and body mass index (for vitamin D), as
      well as age, sex, sunlight exposure, calcium intake, and baseline risk factors for cancer and
      CVD.

      Eligible participants were assigned by chance (like a coin toss) to one of four groups: (1)
      daily vitamin D and omega-3; (2) daily vitamin D and omega-3 placebo; (3) daily vitamin D
      placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. Participants had an
      equal chance of being assigned to any of these four groups and a 3 out of 4 chance of getting
      at least one active agent.

      Participants in all groups took two pills each day -- one softgel that contained either
      vitamin D or vitamin D placebo and one capsule that contained either omega-3 or omega-3
      placebo. Participants received their study pills in convenient calendar packages via U.S.
      mail.

      Participants fill out a short (15-20 minute) questionnaire each year. The questionnaire asks
      about health; lifestyle habits such as physical exercise, diet, and smoking; use of
      medications and dietary supplements; family history of illness, and new medical diagnoses. We
      request consent for medical record review to confirm endpoints. Occasionally, participants
      may receive a phone call from study staff to collect information or to clarify responses on
      the questionnaire.

      At baseline, 16,954 VITAL participants provided an optional blood sample. Approximately 6,000
      of these participants provided a follow-up blood sample during years 1-5 of the trial.

      At baseline, year 2, and year 4 of the trial, a subcohort of 1,054 VITAL participants living
      within driving distance of Boston, Massachusetts received detailed in-clinic health
      assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's
      Hospital. During CTSC visits, participants had a clinical exam, including measurement of
      height, weight, other anthropometrics, blood pressure, and physical performance. They also
      provided fasting blood and urine samples, and underwent 2-hour oral glucose tolerance
      testing, lung function testing (spirometry), electrocardiograms, bone mineral density
      testing, 2D-echocardiography, and assessments of thinking and mood.

      VITAL is supported by funding from the National Cancer Institute, National Heart, Lung and
      Blood Institute, Office of Dietary Supplements, National Institute of Neurological Disorders
      and Stroke, and the National Center for Complementary and Integrative Health. Pharmavite LLC
      of Northridge, California (vitamin D) and Pronova BioPharma (BASF) of Norway (Omacor® fish
      oil) donated the study agents, matching placebos, and packaging in the form of calendar
      packs.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Actual">November 10, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Invasive Cancer of Any Type</measure>
    <time_frame>5 years</time_frame>
    <description>Invasive cancer of any type</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Major Cardiovascular Event</measure>
    <time_frame>5 years</time_frame>
    <description>Major cardiovascular event = a composite endpoint of myocardial infarction, stroke, and death from cardiovascular causes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died From Invasive Cancer of Any Type</measure>
    <time_frame>5 years</time_frame>
    <description>Death from invasive cancer of any type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Female Participants With Breast Cancer</measure>
    <time_frame>5 years</time_frame>
    <description>Breast cancer (in women)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Male Participants With Prostate Cancer</measure>
    <time_frame>5 years</time_frame>
    <description>Prostate cancer (in men)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Colorectal Cancer</measure>
    <time_frame>5 years</time_frame>
    <description>Colorectal cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiovascular Event in Expanded Composite Cardiovascular Endpoint</measure>
    <time_frame>5 years</time_frame>
    <description>Expanded composite cardiovascular endpoint = a composite endpoint of myocardial infarction, stroke, death from cardiovascular causes, and coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>5 years</time_frame>
    <description>Myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stroke</measure>
    <time_frame>5 years</time_frame>
    <description>Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died From Cardiovascular Causes</measure>
    <time_frame>5 years</time_frame>
    <description>Death from cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died From Any Cause</measure>
    <time_frame>5 years</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Invasive Cancer of Any Type, Excluding First 2 Years of Follow-up</measure>
    <time_frame>5 years, excluding first 2 years of follow-up</time_frame>
    <description>Invasive cancer of any type, excluding first 2 years of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Major Cardiovascular Event, Excluding First 2 Years of Follow-up</measure>
    <time_frame>5 years, excluding first 2 years of follow-up</time_frame>
    <description>Major cardiovascular event = a composite endpoint of myocardial infarction, stroke, and death from cardiovascular causes; excluding first 2 years of follow-up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants Who Died From Invasive Cancer of Any Type, Excluding First 2 Years of Follow-up</measure>
    <time_frame>5 years, excluding first 2 years of follow-up</time_frame>
    <description>Death from invasive cancer of any type, excluding first 2 years of follow-up</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Who Died From Any Cause, Excluding First 2 Years of Follow-up</measure>
    <time_frame>5 years, excluding first 2 years of follow-up</time_frame>
    <description>Death from any cause, excluding first 2 years of follow-up</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Percutaneous Coronary Intervention</measure>
    <time_frame>5 years</time_frame>
    <description>Percutaneous coronary intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Coronary-artery Bypass Grafting</measure>
    <time_frame>5 years</time_frame>
    <description>Coronary-artery bypass grafting</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Total Coronary Heart Disease</measure>
    <time_frame>5 years</time_frame>
    <description>Total coronary heart disease = a composite of myocardial infarction, coronary revascularization (percutaneous coronary intervention or coronary-artery bypass grafting), and death from coronary heart disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Ischemic Stroke</measure>
    <time_frame>5 years</time_frame>
    <description>Ischemic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Hemorrhagic Stroke</measure>
    <time_frame>5 years</time_frame>
    <description>Hemorrhagic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Who Died From Myocardial Infarction</measure>
    <time_frame>5 years</time_frame>
    <description>Death from myocardial infarction</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Who Died From Coronary Heart Disease</measure>
    <time_frame>5 years</time_frame>
    <description>Death from coronary heart disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Who Died From Stroke</measure>
    <time_frame>5 years</time_frame>
    <description>Death from stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Myocardial Infarction, Excluding First 2 Years of Follow-up</measure>
    <time_frame>5 years, excluding first 2 years of follow-up</time_frame>
    <description>Myocardial infarction, excluding first 2 years of follow-up</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Colorectal Adenoma</measure>
    <time_frame>5 years</time_frame>
    <description>Colorectal adenoma</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25871</enrollment>
  <condition>Cancer</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>Vitamin D3 (cholecalciferol), 2000 IU per day.</description>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 fatty acids (fish oil)</intervention_name>
    <description>Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 placebo</intervention_name>
    <description>Vitamin D placebo</description>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil placebo</intervention_name>
    <description>Fish oil placebo</description>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        To be eligible for the study, respondents had to, at study entry,:

          1. be men aged 50 or older or women aged 55 or older;

          2. have no history of cancer (except non-melanoma skin cancer), heart attack, stroke,
             transient ischemic attack, angina pectoris, coronary-artery bypass grafting, or
             percutaneous coronary intervention;

          3. have none of the following safety exclusions: history of renal failure or dialysis,
             hypercalcemia, hypo- or hyperparathyroidism, severe liver disease (cirrhosis), or
             sarcoidosis or other granulomatous diseases such as active chronic tuberculosis or
             granulomatosis with polyangiitis (Wegener's);

          4. have no allergy to fish or soy;

          5. have no other serious illness that would preclude participation;

          6. be consuming no more than 800 IU of vitamin D from all supplemental sources combined
             (individual vitamin D supplements, calcium+vitamin D supplements, medications with
             vitamin D [e.g., Fosamax Plus D], and multivitamins), or, if taking, willing to
             decrease or forego such use during the trial;

          7. be consuming no more than 1200 mg/d of calcium from all supplemental sources combined,
             or, if taking, willing to decrease or forego such use during the trial;

          8. not be taking fish oil supplements, or, if taking, willing to forego their use during
             the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JoAnn E. Manson, MD, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie E. Buring, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vitalstudy.org</url>
    <description>VITAL study website</description>
  </link>
  <reference>
    <citation>Bassuk SS, Manson JE, Lee IM, Cook NR, Christen WG, Bubes VY, Gordon DS, Copeland T, Friedenberg G, D'Agostino DM, Ridge CY, MacFadyen JG, Kalan K, Buring JE. Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL). Contemp Clin Trials. 2016 Mar;47:235-43. doi: 10.1016/j.cct.2015.12.022. Epub 2016 Jan 6.</citation>
    <PMID>26767629</PMID>
  </reference>
  <reference>
    <citation>Pradhan AD, Manson JE. Update on the Vitamin D and OmegA-3 trial (VITAL). J Steroid Biochem Mol Biol. 2016 Jan;155(Pt B):252-6. doi: 10.1016/j.jsbmb.2015.04.006. Epub 2015 Apr 9.</citation>
    <PMID>25864623</PMID>
  </reference>
  <reference>
    <citation>Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, Zhang SM, Buring JE. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012 Jan;33(1):159-71. doi: 10.1016/j.cct.2011.09.009. Epub 2011 Oct 2.</citation>
    <PMID>21986389</PMID>
  </reference>
  <reference>
    <citation>Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE; VITAL Research Group. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019 Jan 3;380(1):33-44. doi: 10.1056/NEJMoa1809944. Epub 2018 Nov 10.</citation>
    <PMID>30415629</PMID>
  </reference>
  <reference>
    <citation>Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE; VITAL Research Group. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019 Jan 3;380(1):23-32. doi: 10.1056/NEJMoa1811403. Epub 2018 Nov 10.</citation>
    <PMID>30415637</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2010</study_first_posted>
  <results_first_submitted>November 12, 2019</results_first_submitted>
  <results_first_submitted_qc>January 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 6, 2020</results_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>JoAnn E. Manson, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>vitamin D3</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>fish oil</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>cancer</keyword>
  <keyword>primary prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchers who are interested in collaborating on research that uses VITAL data should visit the &quot;For VITAL Investigators&quot; section of the VITAL website, www.vitalstudy.org.</ipd_description>
    <ipd_url>http://www.vitalstudy.org/Investigators.html</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT01169259/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>401605 initially screened; 39430 eligible to enter run-in; 25871 eligible for randomization; 2x2 factorial design: 12927 assigned to active vit D (of these, 6463 were assigned to active omega-3 FAs and 6464 to placebo omega-3 FAs) &amp; 12944 assigned to placebo vit D (of these, 6470 were assigned to active omega-3 FAs and 6474 to placebo omega-3 FAs)</recruitment_details>
      <pre_assignment_details>The trial included a 3-month placebo run-in period to select participants likely to have excellent compliance. Only individuals who reported taking at least 2/3 of their study pills during the run-in and met other eligibility criteria were randomized into the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACTIVE Vitamin D + ACTIVE Omega-3 Fatty Acids</title>
          <description>ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
        </group>
        <group group_id="P2">
          <title>ACTIVE Vitamin D + PLACEBO Omega-3 Fatty Acids</title>
          <description>ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day</description>
        </group>
        <group group_id="P3">
          <title>PLACEBO Vitamin D + ACTIVE Omega-3 Fatty Acids</title>
          <description>PLACEBO Vitamin D, one capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
        </group>
        <group group_id="P4">
          <title>PLACEBO Vitamin D + PLACEBO Omega-3 Fatty Acids</title>
          <description>PLACEBO Vitamin D, one capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6463"/>
                <participants group_id="P2" count="6464"/>
                <participants group_id="P3" count="6470"/>
                <participants group_id="P4" count="6474"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6463"/>
                <participants group_id="P2" count="6464"/>
                <participants group_id="P3" count="6470"/>
                <participants group_id="P4" count="6474"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACTIVE Vitamin D + ACTIVE Omega-3 Fatty Acids</title>
          <description>ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
        </group>
        <group group_id="B2">
          <title>ACTIVE Vitamin D + PLACEBO Omega-3 Fatty Acids</title>
          <description>ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day</description>
        </group>
        <group group_id="B3">
          <title>PLACEBO Vitamin D + ACTIVE Omega-3 Fatty Acids</title>
          <description>PLACEBO Vitamin D, one capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
        </group>
        <group group_id="B4">
          <title>PLACEBO Vitamin D + PLACEBO Omega-3 Fatty Acids</title>
          <description>PLACEBO Vitamin D, one capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6463"/>
            <count group_id="B2" value="6464"/>
            <count group_id="B3" value="6470"/>
            <count group_id="B4" value="6474"/>
            <count group_id="B5" value="25871"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6463"/>
                    <count group_id="B2" value="6464"/>
                    <count group_id="B3" value="6470"/>
                    <count group_id="B4" value="6474"/>
                    <count group_id="B5" value="25871"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2458"/>
                    <measurement group_id="B2" value="2462"/>
                    <measurement group_id="B3" value="2461"/>
                    <measurement group_id="B4" value="2467"/>
                    <measurement group_id="B5" value="9848"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4005"/>
                    <measurement group_id="B2" value="4002"/>
                    <measurement group_id="B3" value="4009"/>
                    <measurement group_id="B4" value="4007"/>
                    <measurement group_id="B5" value="16023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6463"/>
                    <count group_id="B2" value="6464"/>
                    <count group_id="B3" value="6470"/>
                    <count group_id="B4" value="6474"/>
                    <count group_id="B5" value="25871"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="7.1"/>
                    <measurement group_id="B2" value="67.1" spread="7.0"/>
                    <measurement group_id="B3" value="67.2" spread="7.1"/>
                    <measurement group_id="B4" value="67.1" spread="7.1"/>
                    <measurement group_id="B5" value="67.1" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6463"/>
                    <count group_id="B2" value="6464"/>
                    <count group_id="B3" value="6470"/>
                    <count group_id="B4" value="6474"/>
                    <count group_id="B5" value="25871"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3276"/>
                    <measurement group_id="B2" value="3271"/>
                    <measurement group_id="B3" value="3271"/>
                    <measurement group_id="B4" value="3267"/>
                    <measurement group_id="B5" value="13085"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3187"/>
                    <measurement group_id="B2" value="3193"/>
                    <measurement group_id="B3" value="3199"/>
                    <measurement group_id="B4" value="3207"/>
                    <measurement group_id="B5" value="12786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Not all participants reported race/ethnicity</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Hispanic white</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6329"/>
                    <count group_id="B2" value="6318"/>
                    <count group_id="B3" value="6324"/>
                    <count group_id="B4" value="6333"/>
                    <count group_id="B5" value="25304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4515"/>
                    <measurement group_id="B2" value="4498"/>
                    <measurement group_id="B3" value="4529"/>
                    <measurement group_id="B4" value="4504"/>
                    <measurement group_id="B5" value="18046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6329"/>
                    <count group_id="B2" value="6318"/>
                    <count group_id="B3" value="6324"/>
                    <count group_id="B4" value="6333"/>
                    <count group_id="B5" value="25304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1278"/>
                    <measurement group_id="B2" value="1275"/>
                    <measurement group_id="B3" value="1271"/>
                    <measurement group_id="B4" value="1282"/>
                    <measurement group_id="B5" value="5106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (not African American)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6329"/>
                    <count group_id="B2" value="6318"/>
                    <count group_id="B3" value="6324"/>
                    <count group_id="B4" value="6333"/>
                    <count group_id="B5" value="25304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="245"/>
                    <measurement group_id="B4" value="252"/>
                    <measurement group_id="B5" value="1013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6329"/>
                    <count group_id="B2" value="6318"/>
                    <count group_id="B3" value="6324"/>
                    <count group_id="B4" value="6333"/>
                    <count group_id="B5" value="25304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American/Alaskan Native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6329"/>
                    <count group_id="B2" value="6318"/>
                    <count group_id="B3" value="6324"/>
                    <count group_id="B4" value="6333"/>
                    <count group_id="B5" value="25304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6329"/>
                    <count group_id="B2" value="6318"/>
                    <count group_id="B3" value="6324"/>
                    <count group_id="B4" value="6333"/>
                    <count group_id="B5" value="25304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6463"/>
                    <count group_id="B2" value="6464"/>
                    <count group_id="B3" value="6470"/>
                    <count group_id="B4" value="6474"/>
                    <count group_id="B5" value="25871"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6463"/>
                    <measurement group_id="B2" value="6464"/>
                    <measurement group_id="B3" value="6470"/>
                    <measurement group_id="B4" value="6474"/>
                    <measurement group_id="B5" value="25871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Invasive Cancer of Any Type</title>
        <description>Invasive cancer of any type</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Invasive Cancer of Any Type</title>
          <description>Invasive cancer of any type</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="793"/>
                    <measurement group_id="O2" value="824"/>
                    <measurement group_id="O3" value="820"/>
                    <measurement group_id="O4" value="797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Major Cardiovascular Event</title>
        <description>Major cardiovascular event = a composite endpoint of myocardial infarction, stroke, and death from cardiovascular causes</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Major Cardiovascular Event</title>
          <description>Major cardiovascular event = a composite endpoint of myocardial infarction, stroke, and death from cardiovascular causes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396"/>
                    <measurement group_id="O2" value="409"/>
                    <measurement group_id="O3" value="386"/>
                    <measurement group_id="O4" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died From Invasive Cancer of Any Type</title>
        <description>Death from invasive cancer of any type</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died From Invasive Cancer of Any Type</title>
          <description>Death from invasive cancer of any type</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="187"/>
                    <measurement group_id="O3" value="168"/>
                    <measurement group_id="O4" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Female Participants With Breast Cancer</title>
        <description>Breast cancer (in women)</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Female Participants With Breast Cancer</title>
          <description>Breast cancer (in women)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6547"/>
                <count group_id="O2" value="6538"/>
                <count group_id="O3" value="6547"/>
                <count group_id="O4" value="6538"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="117"/>
                    <measurement group_id="O4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Male Participants With Prostate Cancer</title>
        <description>Prostate cancer (in men)</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day.</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Male Participants With Prostate Cancer</title>
          <description>Prostate cancer (in men)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6380"/>
                <count group_id="O2" value="6406"/>
                <count group_id="O3" value="6386"/>
                <count group_id="O4" value="6400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="219"/>
                    <measurement group_id="O3" value="219"/>
                    <measurement group_id="O4" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Colorectal Cancer</title>
        <description>Colorectal cancer</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Colorectal Cancer</title>
          <description>Colorectal cancer</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiovascular Event in Expanded Composite Cardiovascular Endpoint</title>
        <description>Expanded composite cardiovascular endpoint = a composite endpoint of myocardial infarction, stroke, death from cardiovascular causes, and coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention)</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiovascular Event in Expanded Composite Cardiovascular Endpoint</title>
          <description>Expanded composite cardiovascular endpoint = a composite endpoint of myocardial infarction, stroke, death from cardiovascular causes, and coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="536"/>
                    <measurement group_id="O2" value="558"/>
                    <measurement group_id="O3" value="527"/>
                    <measurement group_id="O4" value="567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>Myocardial infarction</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>Myocardial infarction</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="176"/>
                    <measurement group_id="O3" value="145"/>
                    <measurement group_id="O4" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stroke</title>
        <description>Stroke</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stroke</title>
          <description>Stroke</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="148"/>
                    <measurement group_id="O4" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died From Cardiovascular Causes</title>
        <description>Death from cardiovascular causes</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died From Cardiovascular Causes</title>
          <description>Death from cardiovascular causes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="142"/>
                    <measurement group_id="O4" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died From Any Cause</title>
        <description>Death from any cause</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died From Any Cause</title>
          <description>Death from any cause</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="485"/>
                    <measurement group_id="O2" value="493"/>
                    <measurement group_id="O3" value="493"/>
                    <measurement group_id="O4" value="485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Invasive Cancer of Any Type, Excluding First 2 Years of Follow-up</title>
        <description>Invasive cancer of any type, excluding first 2 years of follow-up</description>
        <time_frame>5 years, excluding first 2 years of follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Invasive Cancer of Any Type, Excluding First 2 Years of Follow-up</title>
          <description>Invasive cancer of any type, excluding first 2 years of follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490"/>
                    <measurement group_id="O2" value="522"/>
                    <measurement group_id="O3" value="536"/>
                    <measurement group_id="O4" value="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Major Cardiovascular Event, Excluding First 2 Years of Follow-up</title>
        <description>Major cardiovascular event = a composite endpoint of myocardial infarction, stroke, and death from cardiovascular causes; excluding first 2 years of follow-up</description>
        <time_frame>5 years, excluding first 2 years of follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Major Cardiovascular Event, Excluding First 2 Years of Follow-up</title>
          <description>Major cardiovascular event = a composite endpoint of myocardial infarction, stroke, and death from cardiovascular causes; excluding first 2 years of follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                    <measurement group_id="O2" value="296"/>
                    <measurement group_id="O3" value="269"/>
                    <measurement group_id="O4" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Died From Invasive Cancer of Any Type, Excluding First 2 Years of Follow-up</title>
        <description>Death from invasive cancer of any type, excluding first 2 years of follow-up</description>
        <time_frame>5 years, excluding first 2 years of follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died From Invasive Cancer of Any Type, Excluding First 2 Years of Follow-up</title>
          <description>Death from invasive cancer of any type, excluding first 2 years of follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12,927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="126"/>
                    <measurement group_id="O4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Died From Any Cause, Excluding First 2 Years of Follow-up</title>
        <description>Death from any cause, excluding first 2 years of follow-up</description>
        <time_frame>5 years, excluding first 2 years of follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died From Any Cause, Excluding First 2 Years of Follow-up</title>
          <description>Death from any cause, excluding first 2 years of follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368"/>
                    <measurement group_id="O2" value="384"/>
                    <measurement group_id="O3" value="371"/>
                    <measurement group_id="O4" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Percutaneous Coronary Intervention</title>
        <description>Percutaneous coronary intervention</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Percutaneous Coronary Intervention</title>
          <description>Percutaneous coronary intervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="162"/>
                    <measurement group_id="O4" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Coronary-artery Bypass Grafting</title>
        <description>Coronary-artery bypass grafting</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Coronary-artery Bypass Grafting</title>
          <description>Coronary-artery bypass grafting</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Total Coronary Heart Disease</title>
        <description>Total coronary heart disease = a composite of myocardial infarction, coronary revascularization (percutaneous coronary intervention or coronary-artery bypass grafting), and death from coronary heart disease</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Coronary Heart Disease</title>
          <description>Total coronary heart disease = a composite of myocardial infarction, coronary revascularization (percutaneous coronary intervention or coronary-artery bypass grafting), and death from coronary heart disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="346"/>
                    <measurement group_id="O3" value="308"/>
                    <measurement group_id="O4" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Ischemic Stroke</title>
        <description>Ischemic stroke</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemic Stroke</title>
          <description>Ischemic stroke</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Hemorrhagic Stroke</title>
        <description>Hemorrhagic stroke</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hemorrhagic Stroke</title>
          <description>Hemorrhagic stroke</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Died From Myocardial Infarction</title>
        <description>Death from myocardial infarction</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died From Myocardial Infarction</title>
          <description>Death from myocardial infarction</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>3.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Died From Coronary Heart Disease</title>
        <description>Death from coronary heart disease</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died From Coronary Heart Disease</title>
          <description>Death from coronary heart disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Died From Stroke</title>
        <description>Death from stroke</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Placebo</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died From Stroke</title>
          <description>Death from stroke</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>2.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Myocardial Infarction, Excluding First 2 Years of Follow-up</title>
        <description>Myocardial infarction, excluding first 2 years of follow-up</description>
        <time_frame>5 years, excluding first 2 years of follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>VItamin D Placebo</title>
            <description>VItamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active Omega-3 Fatty Acids</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Omega-3 Fatty Acids Placebo</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction, Excluding First 2 Years of Follow-up</title>
          <description>Myocardial infarction, excluding first 2 years of follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12927"/>
                <count group_id="O2" value="12944"/>
                <count group_id="O3" value="12933"/>
                <count group_id="O4" value="12938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Colorectal Adenoma</title>
        <description>Colorectal adenoma</description>
        <time_frame>5 years</time_frame>
        <posting_date>11/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>Vit D Monitored safety cond'ns: hypercalcemia, kidney stones, parathyroid disease, kidney failure or dialysis; Other symptoms, side effects: GI bleeding, easy bruising; stomach upset or pain; nausea; constipation, diarrhea, skin rash
Omega-3 FA Monitored safety cond'ns: GI bleeding; blood in urine; easy bruising; freq nosebleeds; kidney failure or dialysis; Other symptoms, side effects: stomach upset or pain; nausea; constipation; diarrhea; skin rash; bad taste in mouth; increased burping</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Vitamin D</title>
          <description>Vitamin D3, one 2000 IU capsule/day</description>
        </group>
        <group group_id="E2">
          <title>Vitamin D Placebo</title>
          <description>Vitamin D placebo, one capsule/day</description>
        </group>
        <group group_id="E3">
          <title>Active Omega-3 Fatty Acids</title>
          <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
        </group>
        <group group_id="E4">
          <title>Omega-3 Fatty Acids Placebo</title>
          <description>Omega-3 fatty acids placebo, one capsule/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="485" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="493" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="493" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="485" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1673" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="1659" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="1613" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="1619" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="341" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="403" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="370" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="374" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="151" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="139" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Invasive cancer of any type</sub_title>
                <description>Total cancer=invasive cancer of any type</description>
                <counts group_id="E1" subjects_affected="793" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="824" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="820" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="797" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Death from cancer</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="173" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Breast cancer (in women)</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="6547"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="6538"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="6547"/>
                <counts group_id="E4" subjects_affected="129" subjects_at_risk="6538"/>
              </event>
              <event>
                <sub_title>Prostate cancer (in men)</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="6380"/>
                <counts group_id="E2" subjects_affected="219" subjects_at_risk="6406"/>
                <counts group_id="E3" subjects_affected="219" subjects_at_risk="6386"/>
                <counts group_id="E4" subjects_affected="192" subjects_at_risk="6400"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Major cardiovascular event</sub_title>
                <description>Major cardiovascular event = a composite endpoint of myocardial infarction, stroke, and death from cardiovascular causes</description>
                <counts group_id="E1" subjects_affected="396" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="409" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="386" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="419" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="145" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="200" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="148" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="142" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Death from cardiovascular causes</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="142" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="148" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10086" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="10098" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="10094" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="10090" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Easy bruising</sub_title>
                <counts group_id="E1" subjects_affected="3434" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="3408" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="3443" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="3399" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Frequent nosebleeds</sub_title>
                <counts group_id="E1" subjects_affected="466" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="490" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="465" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="491" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Blood in urine</sub_title>
                <counts group_id="E1" subjects_affected="911" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="882" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="919" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="874" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Parathyroid condition</sub_title>
                <description>Parathyroid condition = hyperparathyroidism or hypoparathyroidism</description>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach upset or pain</sub_title>
                <counts group_id="E1" subjects_affected="4860" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="4870" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="4887" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="4843" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3519" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="3589" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="3558" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="3550" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5133" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="5162" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="5184" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="5111" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5511" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="5668" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="5599" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="5580" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Increased burping</sub_title>
                <counts group_id="E1" subjects_affected="2168" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="2207" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="2217" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="2158" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bad taste in mouth</sub_title>
                <counts group_id="E1" subjects_affected="2195" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="2290" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="2240" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="2245" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney stones</sub_title>
                <counts group_id="E1" subjects_affected="477" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="426" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="430" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="473" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Kidney failure or dialysis</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" subjects_affected="3268" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="3430" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="3331" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="3367" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VITAL Study Director</name_or_title>
      <organization>Brigham and Women's Hospital; 900 Commonwealth Ave, 3rd fl.; Boston, MA 02215</organization>
      <phone>1-800-388-3963</phone>
      <email>vitalstudy@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

